Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head‐to‐Head Randomized Clinical Studies
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Peroxisome proliferator‐activated receptors (PPARs) play an important role in regulating both glucose and lipid metabolism. Agonists for both PPAR γ and PPAR γ have been used to treat dyslipidemia and hyperglycemia, respectively. In addition to affecting glucose metabolism, PPAR γ agonists also regulate lipid metabolism. In this review, we will focus on the randomized clinical trials that directly compared the lipid effects of the thiazolidinedione class of PPAR γ agonists, pioglitazone and rosiglitazone, head‐to‐head either as monotherapy or in combination with other lipid‐altering or glucose‐lowering agents
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. V. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073394 · Cited by 761
Ginsberg, H. N., Le, N. A., Goldberg, I. J., Gibson, J. C., Rubinstein, A., Wang-Iverson, P., Norum, R., & Brown, W. V. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112713 · Cited by 424 · cited 1×
“A decrease in apolipoprotein CIII would lead to an increase in lipoprotein lipase activity, and hence an increase in the hydrolysis of triglycerides and catabolic rate of triglyceride-rich lipoproteins including chylomicrons and VLDL [23].”
BackgroundNagashima, K., Lopez, C., Donovan, D., Ngai, C., Fontanez, N., Bensadoun, A., Fruchart-Najib, J., Holleran, S., Cohn, J. S., Ramakrishnan, R., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523219 · Cited by 201 · cited 8×
“This hypothesis is supported by the observation that pioglitazone increases the lipolysis of VLDL triglycerides without affecting the removal of VLDL particles [22].”
InfluentialLincoff, A. M., Wolski, K., Nicholls, S. J., & Nissen, S. E. (2007) · JAMA · doi:10.1001/jama.298.10.1180 · Cited by 52
Long-term Risk of Cardiovascular Events With Rosiglitazone: A Meta-analysis
Singh, S., Loke, Y. K., & Furberg, C. D. (2007) · JAMA · doi:10.1001/jama.298.10.1189 · Cited by 5
Cited by
Grygiel-Górniak, B. (2014) · Nutrition Journal · doi:10.1186/1475-2891-13-17 · Cited by 1,079
Janani, C., & Ranjitha Kumari, B. D. (2015) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2014.09.015 · Cited by 735
PFAS and Potential Adverse Effects on Bone and Adipose Tissue through Interactions with PPARγ
Kirk, A. B., Michelsen-Correa, S., Rosen, C., Martin, C. F., & Blumberg, B. (2021) · Endocrinology · doi:10.1210/endocr/bqab194 · Cited by 90
“Among these are increased risk of fracture in TZD-treated patients (87, 88), as well as obesity, hepatic steatosis (89, 90), and changes in blood lipids (91).”
Background
Metadata
- Authors
- Deeg, M. A., & Tan, M. H.
- Venue
- PPAR Research
- Publisher
- Wiley
- Published
- 2008-01
- Volume
- 2008
- Issue
- 1
- Pages
- 520465-520465
- ISSN
- 1687-4757 (ISSN-L)
- 1687-4765
- OpenAlex
- W2139782290
- Cited by
- 49
- References
- 8
- FWCI
- 1.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head‐to‐Head Randomized Clinical Studies. https://app.cochat.ai/papers/10.1155/2008/520465
- The paper
- Deeg, M. A., & Tan, M. H. (2008). Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head‐to‐Head Randomized Clinical Studies. PPAR Research. https://doi.org/10.1155/2008/520465
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.